Author/Authors :
Gbadamosi-Akindele, Maryam Department of Medicine - Creighton University - Omaha - NE, USA , Diab, Osama Department of Medicine - Creighton University - Omaha - NE, USA , Kassim, Thamer Department of Medicine - Creighton University - Omaha - NE, USA , Campbell, Jonathon Department of Medicine - Creighton University - Omaha - NE, USA , Mcentire, Dan Department of Medicine - University of Utah - Salt Lake City - UT, USA , Nayfeh, Ali Department of Medicine - Creighton University - Omaha - NE, USA , Hazeem, Mahmoud Abu Department of Medicine - Creighton University - Omaha - NE, USA , Dajani, Abdel Rahman Department of Medicine - Norwalk Hospital - Norwalk - CT, USA , Kerfeld, Mitchell Department of Pathology - Creighton University - Omaha - NE, USA , Alsuwaidan, Adbullah Department of Anesthesia - Mayo Clinic - Rochester - MN, USA
Abstract :
Docetaxel is a commonly used chemotherapeutic agent in a variety of cancer treatment regimens. We present a case of apparentdocetaxel-induced Stevens-Johnson syndrome (SJS) in a patient recently treated for metastatic prostate cancer. This medicationis not classically associated with the development of SJS but in our case, along with a number of other case reports, and a singlephase II clinical trial, an association was recognized. We encourage clinicians who employ the use of this medication to beaware of this relationship
Keywords :
Docetaxel-Induced Stevens-Johnson Syndrome , Patient , Metastatic Prostate Adenocarcinoma , Stevens-Johnson syndrome (SJS)
